Nabriva Therapeutics plc Business Operations Contracts & Agreements
17 Contracts & Agreements
- Development Agreements (1 contract)
- Sales Agreements (5)
- Services Agreements (2)
- Supply Agreements (9)
- Third Amendment to API Supply Agreement, dated November 11, 2022, by and between Nabriva Therapeutics Ireland Designated Activity Company and Hovione Limited (Filed With SEC on April 17, 2023)
- Third Amendment to Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International... (Filed With SEC on August 3, 2022)
- Side Agreement to Manufacturing Services Agreement, dated November 19, 2021, by and among Nabriva Therapeutics Ireland DAC and Patheon UK Ltd (Filed With SEC on March 29, 2022)
- First Amendment to API Supply Agreement, dated August 4, 2021, by and between Nabriva Therapeutics Ireland Designated Activity Company and Hovione Limited (Filed With SEC on August 5, 2021)
- Second Amendment to Sales Promotion and Distribution Agreement, dated as of April 12, 2021, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD... (Filed With SEC on August 5, 2021)
- First Amendment to Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International... (Filed With SEC on August 5, 2021)
- Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International GmbH and Merck... (Filed With SEC on August 6, 2020)
- Active Pharmaceutical Ingredient Supply Agreement by and between Nabriva Therapeutics Ireland DAC and Hovione Limited, dated as of November 23, 2018 (Filed With SEC on March 12, 2019)
- Agreement for the Commercial Supply of Products by and between Arran Chemical Company Limited and Nabriva Therapeutics Ireland DAC, dated as of November 12, 2018 (Filed With SEC on March 12, 2019)
- Packaging and Supply Agreement by and between Sharp Corporation and Nabriva Therapeutics US, Inc., dated as of August 30, 2018 (Filed With SEC on November 6, 2018)
- Manufacturing and Supply Agreement by and between Zavante Therapeutics, Inc. and Fisiopharma, S.r.l., dated as of April 14, 2017 (Filed With SEC on November 6, 2018)
- Amended and Restated Pharmaceutical Manufacturing and Exclusive Supply Agreement by and between Laboratorios ERN, S.A. and Zavante Therapeutics, Inc. dated as of July 28, 2016, as... (Filed With SEC on November 6, 2018)
- Manufacturing and Supply Agreement by and between Zavante Therapeutics, Inc. and Ercros, S.A., dated as of July 28, 2016 (Filed With SEC on November 6, 2018)
- Controlled Equity OfferingSM Sales Agreement, dated March 16, 2018, by and between Nabriva Therapeutics plc and Cantor Fitzgerald & Co (Filed With SEC on March 16, 2018)
- Key Intermediate Supply Agreement, dated of August 28, 2017 by and among Nabriva Therapeutics Ireland DAC, and SEL Biochem Xinjiang Co., Ltd, and Fountain International... (Filed With SEC on March 16, 2018)
- Master Agreement for the Manufacture, Packaging and Supply of Products, dated August 7, 2017, by and between ALMAC Pharma Services Limited and Nabriva Therapeutics Ireland DAC (Filed With SEC on March 16, 2018)
- Manufacturing Services Agreement, dated May 8, 2017, by and between Patheon UK Limited and Nabriva Therapeutics AG (Filed With SEC on March 16, 2018)
